Capula Management LTD Bristol Myers Squibb CO Transaction History

Capula Management LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $53,643 - $59,563	-842 Reduced 1.18%	70,603 $4.52 Million
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $10.1 Million - $11.5 Million	-153,868 Reduced 68.29%	71,445 $4.95 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $15.4 Million - $18.3 Million	225,313 New	225,313 $16.2 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $74,290 - $81,819	1,023 New	1,023 $79,000
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $1.8 Million - $2.1 Million	-33,586 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $965,772 - $1.13 Million	16,322 Added 94.54%	33,586 $1.99 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $857,205 - $933,497	13,846 Added 405.09%	17,264 $1.15 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $402,621 - $452,830	-6,785 Reduced 66.5%	3,418 $216,000
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $4.93 Million - $5.58 Million	-85,355 Reduced 89.32%	10,203 $633,000
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $1.4 Million - $1.64 Million	-25,566 Reduced 21.11%	95,558 $5.62 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $5.62 Million - $8.17 Million	121,124 New	121,124 $6.75 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

Stay updated on Capula Management LTD with notifications on news.